Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
208 hedge funds and large institutions have $3.06B invested in Turning Point Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 94 funds opening new positions, 44 increasing their positions, 61 reducing their positions, and 38 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 2 → 10 (+8)
147% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 38
147% more capital invested
Capital invested by funds: $1.24B → $3.06B (+$1.82B)
34% more funds holding
Funds holding: 155 → 208 (+53)
28% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 61
59% less call options, than puts
Call options by funds: $16.7M | Put options by funds: $40.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$51.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$51.6M |
| 3 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$45.7M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$41M |
| 5 |
SFM
Soros Fund Management
New York
|
+$36.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$134M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$94.2M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$72.9M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$68.9M |
| 5 |
State Street
Boston,
Massachusetts
|
-$65.3M |
TPTX Hedge Fund Activity: Q2 2022 in Review
208 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q2 2022, worth a combined $3.06B — up 147% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new TPTX positions and 38 closed out — a net gain of 56 holders — while 44 added to existing stakes and 61 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $51.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $134M.
- 208 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q2 2022, up from 155 in Q1 2022.
- Funds reported $3.06B of Turning Point Therapeutics, Inc. Common Stock stock for Q2 2022, up 147% quarter-over-quarter.
- 94 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q2 2022 and 38 closed out, a net change of +56 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q2 2022 was Fidelity International, an estimated $51.7M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q2 2022 was T. Rowe Price Associates, an estimated $134M sold.
Based on aggregated 13F filings for Q2 2022.